Norges Bank’s United Therapeutics UTHR Stock Holding History

Norges Bank’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-602,191	Closed	-$293M	–	1346
2025 Q4	$293M	Buy	+602,191	New	+$280M	0.03%	427
2025 Q3	–	Sell	-474,868	Closed	-$136M	–	1502
2025 Q2	$136M	Buy	474,868 +8,515	+2%	+$2.54M	0.02%	597
2025 Q1	$144M	Buy	466,353 +36,231	+8%	+$12.4M	0.02%	542
2024 Q4	$152M	Buy	430,122 +6,490	+2%	+$2.39M	0.02%	542
2024 Q3	$152M	Buy	423,632 +384,701	+988%	+$130M	0.02%	537
2024 Q2	$12.4M	Sell	38,931 -425,606	-92%	-$113M	﹤0.01%	1339
2024 Q1	$107M	Buy	464,537 +7,405	+2%	+$1.67M	0.02%	626
2023 Q4	$101M	Buy	457,132 +19,163	+4%	+$4.42M	0.02%	600
2023 Q3	$98.9M	Buy	437,969 +33,142	+8%	+$7.63M	0.02%	566
2023 Q2	$89.4M	Buy	404,827 +8,711	+2%	+$1.93M	0.02%	610
2023 Q1	$88.7M	Sell	396,116 -50,350	-11%	-$12.4M	0.02%	580
2022 Q4	$124M	Buy	446,466 +26,639	+6%	+$6.72M	0.03%	475
2022 Q3	$87.9M	Buy	419,827 +12,169	+3%	+$2.72M	0.02%	553
2022 Q2	$96.1M	Sell	407,658 -8,527	-2%	-$1.73M	0.02%	537
2022 Q1	$74.7M	Sell	416,185 -15,715	-4%	-$2.99M	0.02%	687
2021 Q4	$93.3M	Buy	431,900 +16,369	+4%	+$3.21M	0.02%	647
2021 Q3	$76.7M	Sell	415,531 -5,799	-1%	-$1.14M	0.02%	729
2021 Q2	$75.6M	Sell	421,330 -56,758	-12%	-$10.8M	0.02%	753
2021 Q1	$80M	Buy	478,088 +89,762	+23%	+$15M	0.02%	729
2020 Q4	$58.9M	Sell	388,326 -16,180	-4%	-$2.12M	0.01%	864
2020 Q3	$40.9M	Sell	404,506 -34,432	-8%	-$3.78M	0.01%	950
2020 Q2	$53.1M	Sell	438,938 -88,862	-17%	-$10M	0.02%	795
2020 Q1	$50M	Hold	527,800	–	–	0.02%	701
2019 Q4	$46.5M	Buy	527,800 +13,182	+3%	+$1.16M	0.01%	966
2019 Q3	$41M	Buy	514,618 +16,608	+3%	+$1.34M	0.01%	984
2019 Q2	$38.9M	Hold	498,010	–	–	0.01%	1045
2019 Q1	$58.5M	Hold	498,010	–	–	0.02%	767
2018 Q4	$54.2M	Buy	498,010 +44,249	+10%	+$5.13M	0.02%	700
2018 Q3	$58M	Hold	453,761	–	–	0.02%	755
2018 Q2	$51.3M	Hold	453,761	–	–	0.02%	814
2018 Q1	$51M	Hold	453,761	–	–	0.02%	781
2017 Q4	$67.1M	Buy	453,761 +29,808	+7%	+$3.79M	0.02%	639
2017 Q3	$49.7M	Buy	423,953 +43,726	+11%	+$5.58M	0.02%	778
2017 Q2	$49.3M	Buy	380,227 +38,274	+11%	+$4.77M	0.02%	750
2017 Q1	$46.3M	Sell	341,953 -104,085	-23%	-$15.8M	0.02%	745
2016 Q4	$64M	Buy	446,038 +3,084	+0.7%	+$394K	0.03%	569
2016 Q3	$50M	Sell	442,954 -7,822	-2%	-$940K	0.02%	650
2016 Q2	$47.7M	Sell	450,776 -12,414	-3%	-$1.38M	0.02%	662
2016 Q1	$51.6M	Buy	463,190 +42,050	+10%	+$5.32M	0.03%	609
2015 Q4	$66M	Buy	421,140 +35,616	+9%	+$5.18M	0.03%	493
2015 Q3	$50.6M	Hold	385,524	–	–	0.03%	580
2015 Q2	$67.1M	Sell	385,524 -18,347	-5%	-$3.3M	0.03%	525
2015 Q1	$69.6M	Sell	403,871 -22,155	-5%	-$3.38M	0.03%	523
2014 Q4	$55.2M	Buy	426,026 +30,835	+8%	+$3.97M	0.03%	596
2014 Q3	$50.8M	Sell	395,191 -266,685	-40%	-$27.5M	0.03%	611
2014 Q2	$58.6M	Buy	661,876 +362,273	+121%	+$34.8M	0.02%	905
2014 Q1	$28.2M	Hold	299,603	–	–	0.02%	898
2013 Q4	$33.9M	Buy	299,603 +11,288	+4%	+$1.02M	0.02%	783
2013 Q3	$22.7M	Buy	288,315 +86,785	+43%	+$6.34M	0.01%	1001
2013 Q2	$13.3M	Buy	+201,530	New	+$13M	0.01%	1298

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Norges Bank's UTHR Position: Q1 2026 in Review

Norges Bank sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 602,191 shares — an estimated $293M sold.

Norges Bank first reported a position in UTHR in Q2 2013 and held it in 50 quarters. The position peaked at $293M in Q4 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

Norges Bank reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
Norges Bank sold 602,191 United Therapeutics shares in Q1 2026, an estimated $293M.
Norges Bank first reported a position in United Therapeutics in Q2 2013 and held it in 50 quarters.
Norges Bank's United Therapeutics position peaked at $293M in Q4 2025.
850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Norges Bank's 13F filing for Q1 2026.